NetwoRx Bio
Revolutionizing immunotherapy trials with AI-driven drug–indication–biomarker insights.
Company Overview
Snapshot
Founded in May 2024 by Ori Choshen, NetwoRx Bio operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its core technology for immunotherapy.
Business overview
NetwoRx Bio is a Health Tech & Life Sciences company that leverages cutting-edge computational biology and AI-driven analytics to decode complex communication networks within the tumor microenvironment. The company generates a proprietary NetwoRx Score, a patient-specific metric that identifies actionable molecular interactions to predict response to various immunotherapeutic treatments. This technology aims to optimize clinical trial design by matching immunotherapeutic drugs to the right indications and patient populations, and to deliver precision medicine by identifying patients most likely to benefit from specific treatments. NetwoRx Bio operates in the pharmaceuticals and biotechnology sectors, serving the healthcare and life sciences industries across Europe, Americas, and Asia.
Log in to access full profile ›Company Intelligence Q&A
- What is NetwoRx Bio's primary focus?
- NetwoRx Bio focuses on revolutionizing immunotherapy trials by applying AI-driven insights to drug-indication-biomarker identification, aiming to enhance trial success and personalize treatments.
- When was NetwoRx Bio founded?
- NetwoRx Bio was founded in May 2024.
- Who are the founders of NetwoRx Bio?
- Ori Choshen is a co-founder of NetwoRx Bio.
- What technology does NetwoRx Bio utilize?
- NetwoRx Bio harnesses cutting-edge computational biology and advanced AI-driven analytics to understand the tumor microenvironment and predict treatment responses.
- What is the NetwoRx Score?
- The NetwoRx Score is a proprietary, patient-specific metric generated by NetwoRx Bio's platform that identifies actionable molecular interactions to predict response to various immunotherapies.